[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Danone Nutricia SpA Società Benefit\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100539854","effectiveness-and-impact-on-the-quality-of-life-of-ketogenic-diet-in-pediatric-patients-100539854",false,"NCT06309251","Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients","Clinical and Nutritional Effectiveness and Impact on the Quality of Life of the Ketogenic Diet in Pediatric Patients With Neurological, Genetic or Metabolic Disorders: a Multicenter Prospective Observational Study","Inclusion Criteria:\n\n* Pediatric patients (aged \\\u003C 18 years) with drug-resistant epilepsy (fail to achieve (and maintain) seizure freedom with adequate trials of two or more antiseizure medications) or genetic, metabolic, neurological (congenital and acquired) diseases treated with ketogenic diet\n* Pediatric patients (aged \\\u003C 18 years) with metabolic, genetic or neurological (congenital and acquired) diseases (not necessarily associated with drug-resistant epilepsy) treated with ketogenic diet; this includes the new KD indications or the administration of KD in the ICU for status epilepticus.\n\nExclusion Criteria:\n\n* Patients affected by beta-oxidation cycle disorders, systemic primary carnitine deficiency, primary dyslipidemia, pyruvate carboxylase deficiency, porphyria, mitochondrial disease, defects in ketone body metabolism (ketogenesis or ketolysis), defect in gluconeogenesis.\n* Children with type 1 diabetes\n* Parents (or caregivers) unable to guarantee adherence to the","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.\n\nThe main question\\[s\\] it aims to answer are:\n\n* does KD support adequate growth?\n* does KD improve clinical symptoms?\n* how does KD impact quality of life? Participants will be followed up as per clinical practice",[24,25,26,27],"Drug Resistant Epilepsy","Autism Spectrum Disorder","Chronic Migraine","Brain Tumor, Pediatric","RECRUITING","2025-08-26",{"date":31,"type":32},"2025-09-03","ACTUAL",{"date":34,"type":32},"2022-03-01",{"date":36,"type":20},"2026-12-31",{"name":38,"class":39},"Danone Nutricia SpA Società Benefit","INDUSTRY",3,""]